Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
Open Access
- 18 November 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 116 (20) , 4077-4085
- https://doi.org/10.1182/blood-2010-04-277269
Abstract
Zosuquidar, which modulates P-glycoprotein (P-gp) with minimal delay of anthracycline clearance, may reverse P-gp–mediated resistance in acute myeloiKeywords
This publication has 41 references indexed in Scilit:
- The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trialBritish Journal of Haematology, 2009
- The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBlood, 2005
- MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemiaBritish Journal of Haematology, 2005
- A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced MalignancyClinical Cancer Research, 2004
- Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)Journal of Clinical Oncology, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferationLeukemia, 2002
- Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trialBritish Journal of Haematology, 2001
- MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemiaBritish Journal of Haematology, 1997
- Modulation of multidrug resistance in de novo adult acute myeloid leukemia: Variable efficacy of reverting agents in vitroBlood Reviews, 1995